Bicalutamide - CAS 90357-06-5
Catalog number:
90357-06-5
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C18H14F4N2O4S
Molecular Weight:
430.37
COA:
Inquire
Targets:
Androgen Receptor
Description:
Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
ICI-176334
MSDS:
Inquire
1. Mechanistic studies on the synthesis of bicalutamide
Nabil Asaad* and Shaun Fillery. Org. Biomol. Chem., 2009, 7, 678–686
Being a hydroxysulfone, bicalutamide (1) may be prepared directly from opening the appropriate epoxide with an aryl sulfinate, or in two steps with a thiolate to give a hydroxythioether which may be oxidised subsequently to the sulfone. Conceptually, these approaches differ only in whether oxidation of sulfur occurs prior to or after the epoxide-opening step, however the reduced nucleophilicity of the sulfinate relative to the thiolate clearly has practical implications. The aim of our studies was to demonstrate that the synthesis of bicalutamide (1)from the chlorohydrin (2) occurs via an intermediate epoxide (3)andthat the anionic sulfur nucleophiles 4-fluorobenzenethiolate (4)and 4-fluorobenzenesulfinate (5) react under the same conditions via the same mechanism. Whilst confirmation of the expected sequential pathway, as opposed to a direct SN2-displacement of chloride by the anionic sulfur nucleophiles, could be inferred from the presence and consumption of the intermediate epoxide in a “one-pot” reaction, we thought it prudent additionally to prepare and study the O-methyl analogue (8) of the chlorohydrin in order to verify that it did not form the O-methyl analogue of bicalutamide.
2. Development of an electrochemical method for the determination of bicalutamide at the SWCNT/CPE in pharmaceutical preparations and human biological fluids
Umar J. Pandit,* Imran Khan, Sneha Wankar, K. K. Raj and S. N. Limaye. Anal. Methods,2015,
Bicalutamide (BIC), N-(4-cyano-3-trifluoromethyl-phenyl)-3-(4-fluoro-phenylsulfonyl)-2-hydroxy-2-methyl-propionamide (Scheme 1), is an orally active potent, well-tolerated, nonsteroidal pure antiandrogen with negligible gastrointestinal intolerance. BIC binds to the androgen receptor (AR) which is essential for the development of male characters and is also a key factor for the development and progression of prostate cancer. BIC is one of the newest nonsteroidal antiandrogenic drugs traded as Caluran, Casodex, Bicaluran, etc.
3. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations
Hongli Liu, Xiaoli An, Shuyan Li, Yuwei Wang, Jiazhong Li* and Huanxiang Liu. Mol. BioSyst., 2015, 11, 3347—3354
To investigate the mechanisms of drug resistance and to explore the reasons why subtle structural differences result in dramatic physiological action changes to aid new drug discovery and treat PCa, in this study, molecular dynamics (MD) simulations are employed to study the interaction modes of R-bicalutamide and S-1 with the WT and W741L AR respectively. Moreover, the binding free energy and energy decomposition are additionally calculated, which can provide further comprehension about the R-bicalutamide switch from an antagonist to an agonist due to W741L mutation, while the molecule S-1 remains agonistic.
4. Cocrystals of the antiandrogenic drug bicalutamide: screening, crystal structures, formation thermodynamics and lattice energies
Artem O. Surov, German L. Perlovich*. CrystEngChem.,2016, 18,4818–4829
Different strategies to improve the aqueous solubility and/or dissolution rate and thus the absorption of the drug have been described in the literature, such as solid dispersions, particle size reduction, development of various nanoparticulate delivery systems, and complexation with cyclodextrins. An alternative approach to overcome the solubility challenge without modification of the pharmacophore structure of an active pharmaceutical ingredient (API) is to develop new crystalline forms such as polymorphs, solvates, salts or cocrystals. Two polymorphic forms of bicalutamide have been reported and their crystal structures, physico-chemical properties and thermodynamic stability have been investigated. A solvate with dimethyl sulfoxide has been described by Perlovich et al. It should be stressed that bicalutamide represents a good example of an API for which salt formation is limited due to the lack of suitable ionizable groups. In this case, therefore, cocrystallization has great advantages since molecular cocrystals can be formed regardless of the API's ionisable status. To date, however, cocrystal formation for bicalutamide does not seem to have been systematically explored, and only two cocrystals of Bic with 4,4′-bipyridine and trans-1,2-bisIJ4-pyridyl)ethane are known. Unfortunately, these cocrystal formers may hardly be considered as pharmaceutically relevant. Thus, development of novel crystalline forms of bicalutamide with potentially enhanced key physicochemical properties is still of considerable interest.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Androgen Receptor Products


ODM-201
(CAS: 1297538-32-9)

ODM-201 is a new-generation, potent and selective androgen receptor (AR) inhibitor which is potential useful for treatment of castration-resistant prostate canc...

GLPG0492 R enantiomer
(CAS: 1215085-93-0)

The R-enantiomer of GLPG0492 which is a selective androgen receptor modulator, could be effective in decreasing muscle loss.

CAS 1242137-16-1 N-Desmethyl Enzalutamide

N-Desmethyl Enzalutamide
(CAS: 1242137-16-1)

N-desmethyl Enzalutamide is a major metabolite of Enzalutamide. Enzalutamide is an androgen-receptor (AR) antagonist (IC50 = 36 nM) in LNCaP cells that inhibits...

CAS 3546-41-6 Pyrvinium pamoate

Pyrvinium pamoate
(CAS: 3546-41-6)

Pyrvinium pamoate, a nonabsorbed anthelmintic drug, is a potent androgen receptor inhibitor and a selective WNT pathway inhibitor. Pyrvinium pamoate is a potent...

ASC-J9
(CAS: 52328-98-0)

ASC-J9 is an AR degradation enhancer, suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen rece...

CH5137291
(CAS: 1043446-39-4)

CH5137291 is a potent androgen receptor (AR) pure antagonist which did not produce the agonist metabolite with AR nuclear translocation-inhibiting activity. It ...

CAS 915087-33-1 Enzalutamide

Enzalutamide
(CAS: 915087-33-1)

Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM. It inhibits the activity of prostate cancer cell Ars, which over expressed in prostate ...

GLPG0492
(CAS: 1215085-92-9)

GLPG0492, a selective androgen receptor modulator, could be effective in decreasing muscle loss. The treatment study against Duchenne muscular dystrophy of it h...

CAS 1240299-33-5 AZD-3514

AZD-3514
(CAS: 1240299-33-5)

AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patie...

GSK-2881078
(CAS: 1539314-06-1)

GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phas...

ORM-15341
(CAS: 1297537-33-7)

ORM-15341, an androgen receptor antagonist, could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201. IC50...

BMS-564929
(CAS: 627530-84-1)

BMS-564929 is a novel androgen receptor (AR) modulator (Ki= 2.11 nM) which has been advanced to clinical trials for the treatment of age-related functional decl...

CAS 956104-40-8 ARN-509

ARN-509
(CAS: 956104-40-8)

ARN-509, also known as JNJ-56021927, is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby p...

MI-136
(CAS: 1628316-74-4)

MI-136, with the potential to treat refractory prostate cancer, inhibits DHT-induced expression of androgen receptor (AR) target genes. In vitro: Treatment with...

CAS 19608-29-8 Cortexolone 17 alpha-propionate

Cortexolone 17 alpha-propionate
(CAS: 19608-29-8)

Cortexolone 17 alpha-propionate, also called as CB-03-01, belonging to the family of ester derivatives of cortexolone, is a potent and topical and peripherally ...

CAS 34633-34-6 BX341

BX341
(CAS: 34633-34-6)

BX341, also known as bifluranol, is a new fluorinated bibenzyl anti-androgen and one of a series of bibenzyls designed to present some of the hormonal propertie...

CAS 401900-40-1 Andarine

Andarine
(CAS: 401900-40-1)

Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs.

CAS 90357-06-5 Bicalutamide

Bicalutamide
(CAS: 90357-06-5)

Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.

CAS 427-51-0 Cyproterone acetate

Cyproterone acetate
(CAS: 427-51-0)

Cyproterone acetate is a synthetic derivative of 17-hydroxyprogesterone, and acts as an androgen receptor antagonist as well as a weak progesterone receptor ago...

LGD-2226
(CAS: 328947-93-9)

LGD-2226 is a selective androgen receptor modulator used in the treatment of muscle wasting and osteoporosis, shows to have an anabolic effect on muscle and bon...

Chemical Structure

CAS 90357-06-5 Bicalutamide

Quick Inquiry

Verification code

Featured Items